Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
recently emerged virus, which causes mild to severe pneumonia(Wang,
Horby, Hayden & Gao, 2020). One of the most commonly used first-line
treatment in COVID-19 disease is hydroxychloroquine (HCQ) with or
without azithromycin (AZT)(Yao et al., 2020). The HCQ may have a role
between ACE-2 receptor and SARS-COV-2 attachment and may decrease
pro-inflammatory response(Tripathy, Dassarma, Roy, Chabalala &
Matsabisa, 2020).